Frontline Plc (NYSE:FRO ) Q4 2024 Earnings Conference Call February 28, 2025 9:00 AM ET Company Participants Lars Barstad - Chief Executive Officer Inger Klemp - Chief Financial Officer Conference Call Participants Jonathan Chappell - Evercore ISI Omar Nokta - Jefferies Sherif Elmaghrabi - BTIG Lars Barstad Thank you very much, dear all, and thank you for dialing into Frontline's quarterly earnings call. Being in the tanker industry, one is used to evolving and ever changing markets, largely affected by geopolitical events, but it's becoming a little bit exhausting having potential seismic shifts by the hour.
Frontline (FRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Frontline (FRO) stock based on the movements in the options market lately.
Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual disease (MRD)-negative status (100% elimination of cancer cells). The results build on data from the prior trial, in which 100% of frontline patients also achieved remission.
Frontline stock hit a 52-week low this week after Q3 2024 earnings. The maritime oil shipping sector is experiencing volatility and uncertainty. Frontline's Q3 earnings were in line and showed YoY growth, but spot contract prices are decreasing.
Investors need to pay close attention to Frontline (FRO) stock based on the movements in the options market lately.
Frontline plc (FRO) Q3 2024 Earnings Call Transcript
Frontline plc offers a high dividend yield of 12%, but has a history of unpredictable dividend cuts, making it suitable for aggressive investors. Despite geopolitical risks, oil prices are expected to stay above $70/barrel, benefiting midstream companies like FRO, which are crucial for oil transport. Earnings estimates for FRO are positive, with expected 25% YoY revenue growth, but the company has a history of disappointing earnings reports.
Value Investor's Edge Live returns with the latest episode focused on the crude oil shipping sector. Frontline is the largest US-listed crude tanker owner with a roughly $5B market capitalization.
I maintain a Buy rating for Frontline due to its large, modern fleet, strong balance sheet, and attractive dividend yield. FRO's fleet consists of 82 tankers with an average age of 6.2 years. 56% of the ships are equipped with scrubbers. Despite high leverage, FRO's operating figures and cash reserves adequately cover debt service costs, ensuring financial stability.
Frontline plc (NYSE:FRO ) Q2 2024 Earnings Conference Call August 30, 2024 9:00 AM ET Company Participants Lars Barstad - CEO Inger Klemp - CFO Conference Call Participants Jonathan Chappell - Evercore ISI Omar Nokta - Jefferies Operator Good day and thank you for standing by. Welcome to the Second Quarter 2024 Frontline plc Earnings Conference Call.
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine Company anticipates new data set to bolster existing compelling data reported to date, including efficacy outcomes more than double the benchmarks* Outcomes also expected to identify recommended Phase 2 dose APVO436 renamed as mipletamig: Aptevo adopts new generic name for future use SEATTLE, WA / ACCESSWIRE / August 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIRâ„¢ and ADAPTIR-FLEXâ„¢ platform technologies, today, announced initiation of the Company's Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate APVO436 in combination with venetoclax + azacitidine for frontline patients with acute myeloid leukemia (AML). RAINIER will be conducted in two parts.